Investor Relations

Financial Releases

Date Title and Summary Additional Formats
Toggle Summary Intersect ENT Reports Preliminary Full Year 2019 Revenue
MENLO PARK, Calif. --(BUSINESS WIRE)--Jan. 13, 2020-- Intersect ENT, Inc. (NASDAQ: XENT), a company transforming care for patients with ear, nose and throat conditions, today reported preliminary unaudited revenue for the full year ended December 31, 2019 .
View HTML
Toggle Summary Intersect ENT to Present at the 38th Annual J.P. Morgan Healthcare Conference
MENLO PARK, Calif. --(BUSINESS WIRE)--Dec. 11, 2019-- Intersect ENT, Inc. (Nasdaq: XENT), today announced that management will participate in the 38 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at the Westin St. Francis Hotel in San Francisco , and will present at 1:30
View HTML
Toggle Summary Intersect ENT to Present at the 31st Annual Piper Jaffray Healthcare Conference
MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 19, 2019-- Intersect ENT, Inc. (NASDAQ: XENT ) today announced that management will participate in the 31 st Annual Piper Jaffray Healthcare Conference on December 4 at the Lotte New York Palace Hotel in New York City , and will present in a session at
View HTML
Toggle Summary Intersect ENT Reports Third Quarter 2019 Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 1, 2019-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today reported financial results for the third quarter ended September 30, 2019 .
View HTML
Toggle Summary Intersect ENT to Report Third Quarter 2019 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Oct. 17, 2019-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it will release third quarter financial results on November 1, 2019 .
View HTML
Toggle Summary Intersect ENT Reports Second Quarter 2019 Results
CMS Assigns New J Code for SINUVA and PROPEL, Effective October 1 MENLO PARK, Calif. --(BUSINESS WIRE)--Aug. 1, 2019-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today reported financial results for the second
View HTML
Toggle Summary Intersect ENT to Report Second Quarter 2019 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Jul. 15, 2019-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it will release second quarter financial results on August 1, 2019 .
View HTML
Toggle Summary Intersect ENT Reports First Quarter 2019 Results
MENLO PARK, Calif. --(BUSINESS WIRE)--May 6, 2019-- Intersect ENT ® , Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today reported financial results for the first quarter ended March 31, 2019 .
View HTML
Toggle Summary Intersect ENT to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 25, 2019-- Intersect ENT, Inc. (Nasdaq: XENT) today announced that management will participate in the 2019 Bank of America Merrill Lynch Health Care Conference on Tuesday, May 14, 2019 at the Encore Hotel in Las Vegas , including a Q&A session at 1:40 p.m.
View HTML
Toggle Summary Intersect ENT to Report First Quarter 2019 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 23, 2019-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it will release first quarter financial results on May 6, 2019 .
View HTML